A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: Factors associated with virological response and mutations selected at failure

International Journal of Antimicrobial Agents

Volumn 42, Issue 1, 2013, Pages 42-47

  Marcelin, Anne Geneviève ^a,p   Delaugerre, Constance ^b   Beaudoux, Céline ^a   Descamps, Diane ^a   Morand Joubert, Laurence ^a   Amiel, Corinne ^a   Schneider, Veronique ^a   Ferre, Virginie ^c   Izopet, Jacques ^d   Si Mohamed, Ali ^e   Maillard, Anne ^f   Henquell, Cécile ^g   Desbois, Delphine ^h   Lazrek, Mouna ⁱ   Signori Schmuck, Anne ^j   Rogez, Sylvie ^k   Yerly, Sabine ^l   Trabaud, Mary Anne ^m   Plantier, Jean Christophe ⁿ   Fourati, Slim ^a   Houssaini, Allal ^a   Masquelier, Bernard ^o   Calvez, Vincent ^a   Flandre, Philippe ^a   more..

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f RENNES UNIVERSITY HOSPITAL   (France)

^g UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^h HÔPITAL PAUL BROUSSE   (France)

ⁱ LILLE UNIVERSITY HOSPITAL   (France)

^j GRENOBLE UNIVERSITY HOSPITAL   (France)

^k LIMOGES UNIVERSITY HOSPITAL   (France)

^l HUG   (Switzerland)

^m CROIX ROUSSE HOSPITAL   (France)

ⁿ ROUEN UNIVERSITY HOSPITAL   (France)

^o BORDEAUX UNIVERSITY HOSPITAL   (France)

^p PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

more..

Author keywords

Efficacy; HIV 1; Inhibitor; Integrase; Mutations; Raltegravir; Response

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE; LAMIVUDINE; MARAVIROC; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR DISOPROXIL; VIRUS RNA;

ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INTEGRASE GENE; MAJOR CLINICAL STUDY; MALE; PHYLOGENY; PRIORITY JOURNAL; VIRUS LOAD; VIRUS MUTATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION, MISSENSE; PYRROLIDINONES; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD;

EID: 84879218945     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.02.016     Document Type: Article

References (19)

1. V. Summa, A. Petrocchi, F. Bonelli, B. Crescenzi, M. Donghi, and M. Ferrara Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection J Med Chem 51 2008 5843 5855
2. J.L. Lennox, E. DeJesus, A. Lazzarin, R.B. Pollard, J.V. Madruga, and D.S. Berger Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial Lancet 374 2009 796 806
3. R.T. Steigbigel, D.A. Cooper, P.N. Kumar, J.E. Eron, M. Schechter, and M. Markowitz Raltegravir with optimized background therapy for resistant HIV-1 infection N Engl J Med 359 2008 339 354
4. M. Markowitz, B.Y. Nguyen, E. Gotuzzo, F. Mendo, W. Ratanasuwan, and C. Kovacs Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study J Acquir Immune Defic Syndr 46 2007 125 133
5. R.T. Steigbigel, D.A. Cooper, H. Teppler, J.J. Eron, J.M. Gatell, and P.N. Kumar Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: Week 96 results of the BENCHMRK 1 and 2 phase III trials Clin Infect Dis 50 2010 605 612
6. F. Caby, N. Valin, A.G. Marcelin, L. Schneider, R. Andrade, and M. Guiguet Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients Scand J Infect Dis 42 2010 527 532
7. A. Capetti, S. Landonio, P. Meraviglia, A. Di Biagio, S. Lo Caputo, and G. Sterrantino 96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience PLoS ONE 7 2012 e39222
8. D. Descamps, C. Delaugerre, B. Masquelier, A. Ruffault, A.G. Marcelin, and J. Izopet Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance J Med Virol 78 2006 153 160
9. D. Armenia, I. Malet, L. Fabeni, S. Reigadas, V. Guillot, and D. Dunn Impact of baseline HIV-1 integrase polymorphisms on virological outcome in a large European cohort of patients starting a raltegravir-containing regimen International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies 7-11 June, Los Cabos, Mexico 2011 Abstract 53
10. C. Charpentier, D. Laureillard, C. Piketty, P. Tisserand, D. Batisse, and M. Karmochkine High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors AIDS 24 2010 867 873
11. D.A. Cooper, R.T. Steigbigel, J.M. Gatell, J.K. Rockstroh, C. Katlama, and P. Yeni Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection N Engl J Med 359 2008 355 365
12. M. Youle, S. Staszweski, B. Clotet, J.R. Arribas, A. Blaxhult, and G. Carosi Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations HIV Clin Trials 7 2006 86 96
13. M. Vray, J.L. Meynard, C. Dalban, L. Morand-Joubert, F. Clavel, and F. Brun-Vézinet Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088) Antivir Ther 8 2003 427 434
14. J.V. Madruga, P. Cahn, B. Grinsztejn, R. Haubrich, J. Lalezari, and A. Mills Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial Lancet 370 2007 29 38
15. B. Clotet, N. Bellos, J.M. Molina, D. Cooper, J.C. Goffard, and A. Lazzarin Efficacy and safety of darunavir-ritonavir at Week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials Lancet 369 2007 1169 1178
16. I. Malet, O. Delelis, M.A. Valantin, B. Montes, C. Soulie, and M. Wirden Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro Antimicrob Agents Chemother 52 2008 1351 1358
17. I. Malet, S. Fourati, L. Morand-Joubert, P. Flandre, M. Wirden, and S. Haim-Boukobza Risk factors for raltegravir resistance development in clinical practice J Antimicrob Chemother 67 2012 2494 2500
18. S. Gallien, C. Delaugerre, I. Charreau, J. Braun, T. Boulet, and A. Barrail-Tran Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia AIDS 25 2011 665 669
19. M.R. Underwood, B.A. Johns, A. Sato, J.N. Martin, S.G. Deeks, and T. Fujiwara The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults J Acquir Immune Defic Syndr 61 2012 297 301